Ashwagandha (<i>Withania somnifera (L.) Dunal</i>) for promoting recovery in long covid: protocol for a randomised placebo-controlled clinical trial (APRIL Trial)
Mallinson PAC, Joshi M, Mathpathi M, Perkins A, Clayton T, Shah AS, Mathur R, Birk N, Dhillon A, Lieber J, Beg SS, Hopkins L, Khan A, Allaham S, Kam VT, Sutaria S, R G, Rajagopala S, Bhamra A, Pillai GKG, Khunti K, Nesari T, Kinra S
BMJ open · 2 citations
How it was studied
- Design
- Randomized controlled trial (classified by our AI screen)
- Studied in
- People
- Main outcome
- Health markers and function
Who paid for it
- Funding
- Independent funding
- Government
- World Health Organization
- University or hospital
- University of Pittsburgh
- University or hospital
- London School of Hygiene and Tropical Medicine
- Government
- Ministry of AYUSH, Government of India
- Government
- National Institute for Health and Care Research
- University or hospital
- Royal Botanical Gardens, Kew
- Government
- Ministry of Ayurveda, Yoga and Naturopathy, Unani, Siddha and Homoeopathy
- Government
- National Medicinal Plants Board, Ministry of AYUSH, Government of India
- University or hospital
- NIHR Leicester Biomedical Research Centre
- Grants
- Ministry of AYUSH, Government of India (CD No. 190 dated 13/08/2021)
Based on 9 listed funder(s).
Publication
- Published
- 2025-04-01 · BMJ Open · vol. 15 · issue 4 · p. e094526
- Publisher
- BMJ
- Cited
- 3 citations · more than 91% of similar papers · 3.4× the field average
- Impact
- Top 10% most cited in its field
- References
- 34 works
- Access
- Open access (journal) · CC-BY
- Research areas
- Phytochemicals and Medicinal Plants · Diverse Scientific Research Studies · Long-Term Effects of COVID-19
- Keywords
- Medicine, Withania somnifera, Placebo, Adverse effect, Clinical trial, Randomized controlled trial, Traditional medicine, Alternative medicine, Internal medicine, Pathology
- MeSH
- humans, withania, plant extracts, treatment outcome, phytotherapy, double-blind method, quality of life, adult, female, male, randomized controlled trials as topic, withanolides, covid-19, sars-cov-2, post-acute covid-19 syndrome, covid-19 drug treatment
23 authors
From GB, US, IN, CH
- Poppy Alice Carson MallinsonLondon School of Hygiene & Tropical Medicine
- Manisha JoshiLondon School of Hygiene & Tropical Medicine
- Mahesh MathpathiLondon School of Hygiene & Tropical Medicine
- Alexander PerkinsLondon School of Hygiene & Tropical Medicine
- Tim C. ClaytonLondon School of Hygiene & Tropical Medicine
- Anoop S.V. ShahLondon School of Hygiene & Tropical Medicine
Abstract
Background
Long covid describes a syndrome of persistent symptoms following COVID-19 and is responsible for substantial healthcare and economic burden. Currently, no effective treatments have been established. Ashwagandha (Withania somnifera (L.) Dunal) is a medicinal herb traditionally used in India for its immune-strengthening and anti-inflammatory properties. Withanolides, a family of steroid-derived molecules unique to Ashwagandha, have been shown to modulate inflammatory pathways in animal models, and several small randomised trials in humans support its effectiveness for reducing symptoms that are also associated with long covid. Therefore, this study aims to assess whether Ashwagandha is effective and safe for improving functional status and reducing symptom burden in adults living with long covid.
Methods
A randomised double-blind placebo-controlled trial will be performed at participating general practice (GP) surgeries and long covid clinics across the UK. Individuals diagnosed with long covid will be screened for eligibility and then randomised 1:1 to take 1000 mg daily of Ashwagandha root extract tablets (standardised to <0.9% withanolides) or matching placebo tablets for 3 months (target, n = 2500). Monthly online surveys will be performed to collect patient-reported outcomes, and monthly safety monitoring, including liver function tests, will be conducted by clinical site teams. The primary outcome of the Post-COVID Functional Status Scale score at 3 months will be assessed by baseline-adjusted ordinal logistic regression, according to a pre-published statistical analysis plan. The secondary outcomes included validated quality of life and long covid symptom scales, work status and productivity and adverse events. The trial has been approved as a Clinical Trial of an Investigational Medicinal Produce by the Medicines and Healthcare Regulatory Authority and by the NHS Research Ethics Committee and Health Research Authority.
Discussion
Treatments for long covid are urgently needed. This trial will robustly evaluate the safety and efficacy of a candidate treatment with a promising efficacy and safety profile. If found to be effective, the findings will likely influence treatment guidelines and improve health outcomes in those living with long covid.
Trial registration number
This trial was pre-registered on 15/08/2022: ISRCTN12368131.
Abstract via Europe PMC. Copyright remains with the authors or publisher (CC BY).
Community trust
Loading…
How much do you trust this study's findings?
Comments
Sign in to rate, comment on or flag this study.Sign inSomething wrong here?
Flag this study if its information, labels or funding look wrong. An editor reviews every flag.
Sign in to rate, comment on or flag this study.Sign inEducational information about published research. Not medical advice, and not a recommendation to start or stop anything.